CXCR1 and non-small cell lung carcinoma: In addition, there are ongoing clinical trials assessing the efficacy of PD-1/PD-L1-blocking antibodies and the small-molecule and orally bioavailable CXCR1/2 inhibitor SX-682 in treating melanoma (NCT03161431), metastatic colorectal cancer (NCT04599140; NCT06149481), pancreatic adenocarcinoma (NCT05604560; NCT04477343) and NSCLC (NCT05570825) (Table 2).